SCHEMBL190948

SCHEMBL190948

Brc1cnc(Nc2nc(-c3ccccn3)cs2)cc1Oc1cccc2ncccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN1 Q92952 2/20 0.49
KCNN2 Q9H2S1 2/20 0.49
KCNN3 Q9UGI6 2/20 0.49
MBD2 Q9UBB5 2/20 0.49
MECP2 P51608 1/20 0.49
SLC2A1 P11166 6/20 0.48
MAPT P10636 4/20 0.47
KMT2A Q03164 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
RAB9A P51151 4/20 0.47
NPC1 O15118 4/20 0.47
TDP1 Q9NUW8 4/20 0.47
MEN1 O00255 3/20 0.47
NFKB1 P19838 3/20 0.47
NFKB2 Q00653 3/20 0.47
RELA Q04206 3/20 0.47
TP53 P04637 3/20 0.47
PPP1CA P62136 2/20 0.47
ALDH1A1 P00352 1/20 0.47
ALPL P05186 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL191010 0.91 NPC1 (0.48) MAPTKMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL190731 0.86 GCK (0.45) MAPTALDH1A1KDM4E
SCHEMBL191400 0.82 GCK (0.44)
SCHEMBL191338 0.78 BRAF (0.37) MAPTKMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL191705 0.78 GCK (0.37) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL2489158 0.77 TGFBR1 (0.37) KCNN1KCNN2KCNN3MBD2MECP2
SCHEMBL190721 0.75 GCK (0.49)
SCHEMBL30745828 0.73 KCNN1 (0.58) KCNN1KCNN2KCNN3MBD2MECP2
SCHEMBL27039908 0.73 KCNN1 (0.58) KCNN1KCNN2KCNN3MBD2MECP2
SCHEMBL190453 0.72 GCK (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 KCNN1 1454/4885KCNN2 1319/4885KCNN3 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.